Figure 1
Plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. *P<0.05 vs. baseline; **P<0.01 vs. baseline; °P<0.05 vs. imidapril; +P<0.01 vs. imidapril. PAI-1, plasminogen activator inhibitor.
Figure 1 | Hypertension Research
